– USA, NC – vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company today announced the appointment of Paul Sekhri to its Board of Directors as President and CEO, effective August 1, 2022.
Rich Nelson, who has been serving as Interim Chief Executive Officer since March 2, 2022, will continue to support the company as EVP, Corporate Development, and as a member of the Board of Directors.
About Paul Sekhri
Paul Sekhri joins vTv as it sets to launch Phase 3 pivotal studies for its most advanced product, TTP399, which was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration in April 2021 as an oral adjunctive therapy for the treatment of T1D.
Paul Sekhri brings nearly 30 years of healthcare experience, including serving as President and CEO of several healthcare companies such as eGenesis, Lycera Corp., and Cerimon Pharmaceuticals, as well as senior business development and strategy roles at Sanofi, Teva Pharmaceutical Industries Ltd., TPG Biotech, Cerimon, Ariad Pharmaceuticals, and Novartis Pharma AG. He has been a director on more than 30 private, public company, and non-profit boards and is currently a Director at Ipsen, S.A., Compugen, Pharming N.V., Veeva Systems, Longboard, Spring Discovery, and eGenesis. Additionally, he is on the Board of Directors of the Metropolitan Opera.
“During my long career as a biotechnology executive, I have been attracted to truly novel therapeutic approaches that address serious medical challenges and/or improve patient care,” commented Paul Sekhri. “T1D is a challenging enough disease for patients to manage without also having to worry about hypoglycemia. A treatment that significantly reduces the risk of hypoglycemia while also improving Hb1Ac would be a significant advance in treating this disease. I look forward to working with the vTv team to initiate and complete our Phase 3 trials.”
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral, small molecule drug candidates. vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes and cystic fibrosis-related diabetes. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease, renal disease, primary mitochondrial myopathy, and pancreatic cancer.
For more information: https://vtvtherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.